CyPA 及 CD147在动脉粥样硬化兔血管重构中的表达

目的探讨亲环素A(Cy PA)/CD147在动脉粥样硬化(AS)兔血管重构中的表达特点。方法新西兰雄性白兔32只(3月龄),随机分为对照组、模型组、液氮冻伤组、高脂饮食组(每组8只)。0周和13周分别检测兔血清CD147和Cy PA表达水平。术后13周处死动物,取血管石蜡包埋切片,行HE、弹力纤维染色,观察血管形态,并做巨噬细胞、Cy PA、CD147免疫组织化学染色。利用计算机图像分析系统观察动脉损伤后血管重构相关指标的变化。结果 13周时模型组、液氮冻伤组、高脂饮食组血Cy PA与CD147水平较同时期对照组均明显升高(P<0.05),尤以模型组为甚。除对照组,其余3组均可见内膜增生,模型组还可见典型AS斑块形成;斑块内及增生内膜均可见Cy PA及CD147的表达。模型组、液氮冻伤组、高脂饮食组最小管腔直径及管腔面积较对照组均明显减小(P<0.05),内膜面积、中膜面积、最大内膜厚度、管腔狭窄度较对照组明显增大(P<0.05)。结论 Cy PA与CD147在AS兔血管重构中的表达明显升高。

Study on the Expression Levels of CXCR4, CXCL12, CD44, and CD147 and Their Potential Correlation with Invasive Behaviors of Pituitary Adenomas

Objective To evaluate the factors of CXCR4, CXCL12, CD44, and CD147 as early potential diagnostic biomarkers by determining their expression levels in invasive and non-invasive pituitary adenomas. Methods Fresh pituitary adenoma specimens were collected from 35 pituitary adenoma （21 invasive and 14 non-invasive） patients who underwent surgical treatment in our Neurosurgery Department between January and April of 2009. The expression levels of CXCR4, CXCL12, CD44, and CD147 were evaluated firstly by flow cytometry, fluorescence microscopy in single cell suspensions, and then by immunohistochemical staining of paraffin tissue sections. Results Flow cytometric analyses showed that the percentage of CXCR4- and CXCL12-positive cells from invasive pituitary adenomas （IPA） was significantly higher in the single cell suspensions than that from non-invasive pituitary adenomas （nlPA） （P〈O.05）. Immunohistochemical staining revealed that CXCR4 and CXCL12 staining index scores of the invasive pituitary adenomas were significantly higher than those of the non-invasive pituitary adenomas （P〈O.05）. In contrast, neither flow cytometry nor immunohistochemical staining demonstrated significant difference between CD44 and CD147 expression levels, respectively. Conclusion Expression levels of CXCR4 and CXCL12 are correlated with the invasiveness of pituitary adenomas. Therefore, rather than CD44 and CD147, CXCR4 and CXCL12 may potentially serve as biomarkers for early detection of pituitary adenomas.

Synthesis and Evaluation of a Novel Small-molecule Compound as an Anticancer Inhibitor of CD147

Objective Cancer is a serious threat to human health. Despite extensive research on cancer treatment,there is a growing demand for new therapies. CD147 is widely involved in tumor development, but it is unclear whether cancer cell malignancy is affected by CD147 expression level. The first compound(AC-73) targeting CD147 could only act on advanced tumors and inhibit metastasis. Therefore, new compounds with better anticancer activity should be explored.Methods Wst-1 assays were used to confirm the effect of novel compounds on proliferation.Apoptosis tests were used to evaluate their proapoptotic capacity. A nude mouse model was used to demonstrate in vivo anticancer activity and safety of the compounds. Western blots were used to suggest a molecule mechanism.Results There is a positive correlation between CD147 expression and tumor cell proliferation. A new compound, HA-08, was synthesized and proved to be more active than AC-73. HA-08 could inhibit cancer cell viability and promote cancer cell apoptosis both in vitro and in vivo. HA-08 induces cancer apoptosis, mainly by disrupting the CD147-CD44 interaction and then down-regulating the JAK/STAT3/Bcl-2 signaling pathway.Conclusion Our results have clarified the tumor specificity of CD147 and its drug target characteristics.The biological profile of HA-08 suggests that this compound could be developed as a potential anticancer agent.

The human leucocyte differentiation antigens (HLDA) workshops: the evolv-ing role of antibodies in research, diagnosis and therapy

The 8^th International Workshop on Human Leucocyte Differentiation Antigens （chaired by HZ and managed by BS） was run over a 4-year period and culminated in a conference in December 2004. Here we review the achievements of the HLDA Workshops and provide links to information on CD molecules and antibodies against them, including the 93 new CDs assigned in the 8^th Workshop. We consider what remains to be achieved （including an estimate of the number of leucocyte surface molecules still to be discovered）, and how the field can best move forward.

Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples

AIM:To make clear whether CD147 (EMMPRIN) expression in pathological tumor samples with a fine-needle aspiration biopsy is useful for pathological diagnosis of early hepatocellular carcinoma (HCC). METHODS:Twenty-two patients (15 men and 7 women; median age 68 years,range 56-81 years) underwent a liver tissue biopsy in order to make a diagnosis of HCC. Paraffin-embedded liver biopsy tissue samples from 22 patients were stained with anti-CD147 antibody,murine monoclonal antibody 12C3 (MAb12C3) for immunohistochemical analysis. An immunohistochemical analysis of CD147 was performed and the degree of staining compared between tumor and non-tumor tissue. In addition,the degree of staining within tumor tissue was compared according to a number of clinicopathological variables. RESULTS:The degree of staining of CD147 was significantly higher in tumor tissues than non-tumor tissues,even in tumors less than 15 mm in diameter.The expression of this protein was significantly elevated in HCC tissue specimens from patients with a low value of serum AST and γ-GTP.

Expressions and clinical significance of CD147 and CK19 in hepatocellular carcinoma

Objective: The aim of this study was to investigate the expressions of CD147 and CK19 in hepatocellular car- cinoma (HCC) and their clinical significance. Methods: The expressions of CD147 and CK19 were determined by tissue microarray and immunohistochemistry (IHC) in 272 cases of HCC and 81 cases of adjacent tumorous tissue. Results: The positive expression of CD147 in HCC and adjacent tumorous tissue was 73.53% (200/272) and 13.58% (11/81) with signifi- cant difference (P < 0.05). The positive expression of CK19 in HCC and adjacent tumorous tissue was 14.34% (39/272) and 0 (0/81) with significant difference (P < 0.05). The positive expression of CD147 were closely correlated to the histological grade, clinical stage, tumor-free survival, diameter of tumor and embolus of cancer in aqueduct or portal vein; but not to the patients' sex, age, liver cirrhosis, AFP level, infection of HBV, lymph node metastasis, number of tumor, invasion liver involucrum and the micro-satellites (P > 0.05). The expression of CK19 in HCC were closely correlate to the tumor-free survival, histological grade, diameter of tumor, liver cirrhosis, micro-satellites, lymph node metastasis and clinical stage; but not to patients' sex, age, number of tumor, invasion liver involucrum, AFP level, infection of HBV and embolus of cancer in aqueduct or portal vein (P > 0.05). Among the patients of positive expression of CD147, the median replacing time and overall survival were 13 and 24 months, lower than 48 and 60 months in the patients of negative expression (P < 0.05). Among the patients of positive expression of CK19, the median replacing time and overall survival were 7 and 13 months, lower than 31 and 42 months in the patients of negative expression (P < 0.05). The expression of CD147 had no correlation with the expression of CK19 (r = 0.061, P = 0.317). Conclusion: The positive of CD147 and CK19 closely correlate with the clinical prognosis of HCC, it may indicate poor prognosis of HCC.

Human ovarian neoplasm cell CD147 stimulates production and activation of matrix metalloproteinases in co-cultures with mouse fibroblasts

Objective: To investigate the expression of CD147 on human ovarian neoplasm cell lines and its influence on production and activation of matrix metallproteinases(MMPs). Methods: The expression of CD147 on different human ovarian neoplasm cell lines was studied by western blotting. Co-culture was carried out to investigate the stimulative effect of the positive expression CD147 cell HO-8910 on the production of MMPs of fibroblast cell in vitro. Zymography and immune blotting were used to study the production and activity of positive MMPs, at the time, to explore the relation between CD147 and MMPs. Results: CD147 was positively presented in 2 ovarian neoplasm cell lines(HO-8910,3-AO), but in SKOV3, TC-1,NIN3T3 cell was negative. MMP-2 and MMP-9 were detected by HO-8910 cell line, mouse fibroblast cell and co-culture cells; but the expression in co-culture cell is obviously higher than individual cultures of each type alone.CD147 stimulated MMPs in dose-dependent manner. Conclusion: CD147 causes increased production and activation of MMP-2, MMP-9.CD147 is probably a indirect marker of some ovarian cancer cells with invasion and metastasis.

The expressions of CD147 and MMP-9 in non-Hodgkin's lymphoma cells and the relation to prognosis

Objective： The aim of this study was to investigate the expression of CD147 and matrix metalioprpteinsae 9 （MMP-9） in children with non-Hodgkin＇s lymphoma （NHL） and the relations between expressions of CD147 ＆ MMP-9 and the clinical indexes. Methods： Specimens excised from NHL patients were prepared. Expression of CD147 and MMP-9 were tested by SABC immunohistochemistry and its correlation to clinical results were analyzed in this report. Results： The positive rate of CD147 expression was 73% （45/62）, and that of MMP-9 expression was 81% （50/62）. There was a positive correlation between CD147 and MMP-9 expressions. CD147 expression intensity was linked to clinical myelo-infiltration, tumor size, LDH value, and clinical staging （P 〈 0.05）, rather than children age, gender, or immune typing （P 〉 0.05）; MMP-9 expression intensity was linked to myelo-infiltration, and clinical staging （P 〈 0.05）, rather than age, gender, immune typing, tumor size, or LDH value （P 〉 0.05）. Five-year survival rates were 78% （22/28） and 45% （15/34） in CD147 （-）-（＋） and （＋＋）-（＋＋＋） cases respectively, and those were 84% （21/25） and 43% （16/37） in MMP-9 （-）-（＋） and （＋＋）-（＋＋＋） cases respectively, the difference was significant. Conclusion： The elevated expression of CD147 and/or MMP-9 correlates with a poor clinical outcome in patients with NHL.

基于TGF-β1/CD147信号探讨慢性束缚应激促小鼠乳腺癌进展及逍遥散调节机制研究

目的基于TGF-β1/CD147信号探讨慢性束缚应激促小鼠乳腺癌进展及逍遥散调节机制。方法40只BABL/c小鼠随机分为移植瘤组(Tumor)、模型组(Model)、逍遥散组(Xiaoyaosan)和米非司酮组(Mifepristone),将4T1细胞株接种于各组小鼠腋下,待成瘤后,除Tumor组外其余各组小鼠均进行慢性束缚应激21天,同时Xiaoyaosan组和Mifepristone组小鼠给予相对应的药物灌胃,Tumor组和Model组小鼠灌胃生理盐水。造模结束后,小鼠麻醉断头处死,测量小鼠瘤体重量和体积、内脏指数;采用ELISA方法检测各组小鼠血清肿瘤标志物糖类抗原ca199(Carbohydrate antigen199,CA199)、癌胚抗原(Carcino-embryonic antigen,CEA)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)的含量,血清多巴胺(Dopamine,DA)和皮质酮(Corticosterone,CORT)的含量,以及肿瘤组织转化生长因子β1(Transforming growth factor-β1,TGF-β1)和白介素10(Interleukin 10,IL-10)的含量。采用免疫组化和Western blot方法检测各组小鼠肿瘤组织巨噬细胞极化标志物诱导型一氧化氮合酶(Inducible nitric oxide synthase,iNOS)和精氨酸酶1(Arginase-1,Arg-1)的表达,以及肿瘤组织中细胞外基质金属蛋白酶诱导剂(Extracellular matrix metalloproteinase inducer,EMMPRIN,CD147)及其下游信号分子基质金属蛋白酶2(Matrix metalloproteinases 2),MMP2、基质金属蛋白酶9(MMP9)和VEGF的表达。结果与Tumor组比较,Model组小鼠肿瘤重量和体积,血清CA199、CEA、VEGF、CORT含量,肿瘤TGF-β1和IL-10含量均显著增加;内脏指数和血清DA含量显著减少;肿瘤巨噬细胞M2型极化标志物Arg-1的表达显著增加,M1型极化标志物iNOS的表达显著降低;肿瘤CD147及其下游信号分子MMP2、MMP9和VEGF蛋白表达显著增加,逍遥散和米非司酮均可有效逆转以上改变。结论慢性束缚应激促小鼠乳腺癌进展的机制与肿瘤相关巨噬细胞M2型极化释放TGF-β1增加、激活CD147及其下游相关信号有关,而逍遥散可缓解应激条件下皮质酮增高引起的巨噬细胞M2型极化,减少TGF-β1的生成,抑制CD147及其下游信号,从而抑制慢性应激引起的小鼠乳腺癌进展。

乳腺浸润性癌中CD147和PHH3的表达与临床病理特征的关系

目的观察浸润性乳腺癌中CD147蛋白的定量表达和PHH3阳性细胞数目,分析二者与多个临床病理特征的关系及相关性。方法选取80例乳腺原发浸润性癌手术切除标本为研究对象,29例正常乳腺组织作为对照组,采用免疫组织化学SP法检测CD147和PHH3的表达,用IPP6.0图像分析软件对CD147蛋白表达进行定量测试,计数PHH3阳性个数和有丝分裂指数,分析浸润性乳腺癌中CD147和PHH3的表达与临床病理特征的关系,用Spearman法分析二者之间的相关性。结果CD147主要定位于乳腺癌细胞胞膜或膜浆,PHH3主要定位于浸润性乳腺癌有丝分裂的细胞核内,二者在浸润性乳腺癌组织中的定量表达和阳性数目均显著高于正常乳腺组织(P=0.000)。80例浸润性乳腺癌中,CD147蛋白定量表达在肿瘤直径较大、WHO分级较高、淋巴结有转移、TNMⅢ-Ⅳ期、雌激素受体(estrogen receptor,ER)阴性、Her-2基因无扩增阳性强度较高(P均<0.05);PHH3阳性数目和有丝分裂指数在肿瘤直径较大、WHO分级较高、淋巴结有转移状况及TNM分期Ⅲ-Ⅳ期(P_(均)<0.05)。CD147蛋白表达越高,PHH3阳性数目相应越多,有丝分裂指数越高,Spearman分析显示CD147分别与PHH3阳性数目和有丝分裂指数呈显著正相关(r=0.950,r=0.706,P=0.000)。结论浸润性乳腺癌中CD147和PHH3高表达,与肿瘤的发生发展有关,二者呈正相关,检测乳腺癌中CD147蛋白定量表达、PHH3阳性数目和有丝分裂指数有助于侵袭和转移的判断,为乳腺癌临床病理诊断提供了参考价值。

CD147通过Akt/mTOR信号通路调控脂肪酸合成对子宫颈癌细胞增殖、侵袭和迁移的影响

目的探讨CD147的表达对子宫颈癌细胞增殖、侵袭、迁移的影响和潜在的分子机制。方法分析UCSC数据库BSG基因(编码CD147蛋白)在子宫颈癌中的表达,采用Log-rank test法评估各组表达的预后差异。应用Western blot法检测CD147在Siha、Hela和H8细胞中的表达,通过慢病毒转染Hela细胞下调CD147表达,并验证其转染效率。运用Western blot法检测各组细胞中p-Akt、p-mTOR、ACC1、FASN、E-cadherin和N-cadherin的表达;使用BODIPY染色和脂肪酸试剂盒检测细胞中脂肪酸含量;利用CCK-8、平板克隆和Transwell实验检测细胞增殖、侵袭和迁移能力。sh-CD147组经Akt激动剂(SC79)处理后,Western blot法检测细胞中p-Akt、p-mTOR、ACC1、FASN、E-cadherin和N-cadherin的表达;选用BODIPY染色和脂肪酸试剂盒检测细胞中脂肪酸含量;利用平板克隆实验和Transwell实验分别检测细胞增殖、侵袭和迁移能力。结果UCSC数据库显示CD147在子宫颈癌中的表达高于正常子宫颈组织(P<0.01);CD147过表达的患者预后不良。Western blot检测结果显示,与H8细胞相比,Siha和Hela细胞中CD147蛋白表达增高(P=0.011)。下调CD147表达后,与Hela组相比,sh-CD147组细胞中CD147、ACC1和FASN蛋白表达降低(P<0.001);BODIPY荧光染色减弱,脂肪酸含量下降(P<0.001);细胞集落形成能力、侵袭和迁移能力降低;sh-CD147组细胞中E-cadherin蛋白表达升高,N-cadherin、p-Akt和p-mTOR表达降低。与sh-CD147相比,经Akt激动剂SC-79剂处理后(sh-CD147-SC79)细胞内p-Akt、p-mTOR、ACC1、FASN和N-cadherin表达升高,E-cadherin表达降低,脂质染色和脂肪酸含量检测结果与关键酶表达一致(P<0.01),细胞增殖、侵袭迁移能力显著增强。结论CD147通过Akt/mTOR信号通路调控脂肪酸合成,促进子宫颈癌细胞增殖、侵袭和迁移。

血清CD147和CXCL1与尿毒症腹膜透析患者发生营养不良及腹膜炎的相关性分析

目的:探讨细胞外基质金属蛋白酶诱导因子(CD147)、炎症趋化因子配体1(CXCL1)在尿毒症腹膜透析患者血清中的表达,以及与发生营养不良及腹膜炎的相关性。方法:选取2020年01月—2021年06月在我院接受治疗的80例尿毒症腹膜透析患者,按照是否发生营养不良分为营养正常组(n=38)和营养不良组(n=42);根据是否发生腹膜炎分为非腹膜炎组(n=57)和腹膜炎组(n=23)。Spearman和Pearson法分析血清CD147、CXCL1水平分别与尿毒症腹膜透析患者发生营养不良及腹膜炎及影响因素相关性;受试者工作特征(ROC)曲线分析血清CD147、CXCL1水平对尿毒症腹膜透析患者发生营养不良及腹膜炎的预测价值。结果:与营养正常组相比,营养不良组年龄、透析龄、C反应蛋白(CRP)、CD147、CXCL1显著升高(P<0.05);总胆固醇(TC)、血清前蛋白(SPA)、白蛋白(Alb)、血红蛋白(Hb)显著降低(P<0.05)。腹膜炎组年龄、透析龄、CRP、CD147、CXCL1显著高于非腹膜炎组(P<0.05);SPA、Alb、Hb显著低于非腹膜炎组(P<0.05)。ROC曲线显示,血清CD147、CXCL1二者联合分别预测尿毒症腹膜透析患者发生营养不良及腹膜炎的敏感度和特异性均显著优于两者各自单独预测(P<0.05)。相关性分析显示血清CD147、CXCL1分别与尿毒症腹膜透析患者发生营养不良及腹膜炎正相关(P<0.05)。结论:发生营养不良及腹膜炎的尿毒症腹膜透析患者血清CD147、CXCL1水平显著升高,二者联合对患者发生营养不良及腹膜炎有较好预测价值。

CD147通过AIM2炎症小体介导宫颈癌细胞焦亡和增殖

目的 探讨跨膜蛋白CD147表达量变化对AIM2炎症小体介导的宫颈癌细胞焦亡及增殖的影响。方法 采用Western blot实验检测CD147在宫颈癌细胞SiHa(HPV+)、C33a(HPV-)和正常宫颈上皮细胞H8(HPV+)、HCer Epic(HPV-)中的表达水平;通过慢病毒转染SiHa细胞下调CD147的表达,根据不同处理分为SiHa组、阴性对照组(shCD147-NON)、敲低组1(shCD147-1)和敲低组2(shCD147-2),通过Western blot、RT-qPCR和观察细胞绿色荧光表达验证转染效果;通过Western blot和RT-qPCR检测CD147和AIM2炎症小体相关因子AIM2、Caspase-1、IL-18、GSDMD蛋白和mRNA的表达;检测细胞培养上清中乳酸脱氢酶(LDH)释放度,荧光倒置显微镜下观察细胞的形态;CCK-8实验检测细胞的增殖能力;细胞克隆实验检测细胞集落形成能力。结果 Western blot结果显示,与HCerEpic细胞比较,SiHa细胞中CD147蛋白表达最高(P <0.05);CD147低表达慢病毒有效下调了SiHa细胞CD147表达水平(P <0.05);Western blot及RT-qPCR实验结果表明,与SiHa组相比,shCD147-1组和shCD147-2组AIM2、Caspase-1、IL-18、GSDMD蛋白和mRNA表达明显升高(P <0.05);乳酸脱氢酶(LDH)释放实验显示,与SiHa组相比,shCD147组LDH释放度明显升高(P <0.05);荧光倒置显微镜下显示,shCD147组出现肿胀和空泡化,表现出典型的细胞焦亡现象;与SiHa组相比,shCD147-1组和shCD147-2组细胞增殖能力和集落形成能力明显降低(P <0.05)。结论 CD147低表达有效上调宫颈癌SiHa细胞AIM2炎症相关因子的表达,诱发细胞焦亡,抑制细胞的增殖和克隆。

SETDB1-mediated CD147-K71 di-methylation promotes cell apoptosis in non-small cell lung cancer

Protein post-translational modifications(PTMs)are at the heart status of cellular signaling events and broadly involved in tumor progression.CD147 is a tumor biomarker with various PTMs,promoting tumor metastasis and metabolism reprogramming.Nevertheless,the relationship between the PTMs of CD147 and apoptosis has not been reported.In our study,we produced a specific anti-CD147-K71 di-methylation(CD147-K71me2)antibody by immunizing with a di-methylated peptide and observed that the level of CD147-K71me2 in non-small cell lung cancer(NSCLC)tissues were lower than that in NSCLC adjacent tissues.SETDB1 was identified as the methyltransferase catalyzing CD147 to generate CD147-K71me2.RNA-seq showed that FOSB was the most significant differentially expressed gene(DEG)between wild-type CD147(CD147-WT)and K71-mutant CD147(CD147-K71R)groups.Subsequently,we found that CD147-K71me2 promoted the expression of FOSB by enhancing the phosphorylation of p38,leading to tumor cell apoptosis.In vivo experiments showed that CD147-K71me2 significantly inhibited tumor progression by promoting cell apoptosis.Taken together,our findings indicate the inhibitory role of CD147-K71me2 in tumor progression from the perspective of post-translational modification,which is distinct from the pro-cancer function of CD147 itself,broadening our perspective on tumor-associated antigen CD147.

SARS-CoV-2靶向CypA/CD147受体途径诱导心肌细胞凋亡

目的探究SARS-CoV-2靶向亲环素A(CypA)/细胞外金属蛋白酶诱导剂(CD147)受体途径诱导心肌细胞凋亡的可能机制。方法构建pEncmv-SARS-CoV-2 S-3xflag重组载体质粒转染H9c2细胞,TUNEL实验、流式细胞术和DNA ladder分析细胞凋亡,免疫共沉淀(CoIP)验证CD147与SARS-CoV-2 S蛋白之间相互作用,Western blotting法检测细胞凋亡信号通路相关蛋白表达。结果与对照组比较,TUNEL实验和流式细胞术结果显示转染组细胞凋亡显著增加(P<0.05),DNA ladder分析发现DNA降解明显。Western blotting法检测显示Caspase12、DR3表达显著升高(P<0.001),FAS表达升高(P<0.01),TRF1、DR4表达降低(P<0.01)。结论SARS-CoV-2 S蛋白靶向CypA/CD147受体入侵宿主细胞,激活内质网通路(Caspase12)和死亡受体通路(DR3、FAS),以内源性和外源性凋亡途径诱导心肌细胞凋亡。

甲状腺癌组织中CD147及survivin表达及其与术后淋巴结转移的相关性

目的探讨甲状腺癌组织中白细胞分化抗原147(CD147)及survivin表达及其与术后淋巴结转移的相关性。方法选取82例甲状腺癌患者作为研究对象,所有患者均行手术治疗,采集肿瘤标本及癌旁正常组织标本进行免疫组织化学检测,比较肿瘤标本及癌旁正常组织标本内CD147及survivin阳性表达差异;术后随访1年,记录淋巴结转移情况,依据淋巴结转移与否分为两组,收集两组患者年龄、性别、肿瘤分期、体质量指数、CD147表达、survivin表达、肿瘤直径等多方面资料,分别进行单因素、Logistic回归分析,获得影响甲状腺癌患者术后淋巴结转移的高危因素。结果肿瘤组织内CD147阳性率、survivin阳性率分别为73.17%、79.27%,高于癌旁正常组织,差异有统计学意义(P<0.05);82例患者术后随访1年,其中30例出现淋巴结转移,52例未出现淋巴结转移;两组肿瘤分期、CD147表达、survivin表达相比,差异有统计学意义(P<0.05);多因素显示,肿瘤分期Ⅲ期、CD147阳性表达、survivin阳性表达为影响甲状腺癌术后淋巴结转移的高危因素(P<0.05且OR>1)。结论CD147及survivin在甲状腺癌中存在较高阳性表达,且两者阳性表达为术后淋巴结转移的高危因素,应于早期开展该项检测,尽早识别危险因素,降低术后淋巴结转移风险。

CCL 4与BDL致大鼠肝损伤中α-SMA、Hab18G/CD147表达的差异

探究CCL 4腹腔注射和胆总管结扎(Bile Duct Ligation,BDL)致大鼠肝损伤中α-SMA、Hab18G/CD147表达的差异,为法医学鉴定药物性肝损伤提供科学参考。选取雄性SD大鼠60只,随机分为CCL 4对照组(N)、BDL对照组(S)、CCL 4肝损伤组(C)、BDL肝损伤组(B),每组各15只。各组分别在实验1 w、3 w、5 w时断颈处死5只大鼠,采血检测谷丙转氨酶(Glutamic pyruvic transaminase,ALT)、谷草转氨酶(Aspertate aminotransferase,AST),总胆红素(Total bilirubin,TBIL)、直接胆红素(Direct bilirubin,DBIL),检测α-SMA、Hab18G/CD147mRNA的表达情况。qRT-PCR检测结果显示,C组α-SMAmRNA、Hab18G/CD147mRNA的表达量在1 w、3 w、5 w同时间段相比均高于B组(P<0.05)。与对照组相比较,C组、B组血清中ALT、AST、DBIL、TBIL含量均增加,说明大鼠肝脏均有不同程度的损伤;CCL 4与BDL肝损伤有不同特点,在肝损伤过程中α-SMA、Hab18G/CD147mRNA的表达随着损伤时间的延长表达量逐渐增加。

LuminalB型乳腺癌原发灶和同侧腋窝淋巴结转移灶中CD147和MMP-2的表达差异及其临床意义

研究细胞外基质金属蛋白酶诱导因子(CD147)和基质金属蛋白酶-2(MMP-2)在luminal B型乳腺癌原发灶和同侧腋窝淋巴结转移灶中的表达差异及其临床意义,探讨CD147及MMP-2在该分型乳腺癌的表达与预后的关系。方法 提取luminal B型的乳腺癌数据,分别对CD147及MMP2进行单基因分析。选取了2013年06月至2018年01月在贵州医科大学附属医院乳腺外科的67名接受手术治疗的女性luminai B型乳腺癌患者。检测其中原发灶与淋巴结转移灶的雌激素受体(ER)、孕酮受体(PR)、人表皮生长因子受体2(HER-2)、Ki-67、CD147和MMP-2的表达。电话随访调查其生存情况。结果 1相关性分析结果表明,MMP-2在淋巴结转移灶中的表达差异与临床分期有关(p<0.05),但与年龄、家族遗传史和肿瘤大小无关(p>0.05);CD147和MMP-2在原发灶和腋窝淋巴结中的表达被分为四个亚组进行分析,CD147和MMP-2的OS(overall survival)总体差异具有统计学意义(p<0.05)。

CD147、MMP-2在胃癌组织中的表达及临床意义

目的 研究胃癌组织中CD147、MMP-2的表达,并分析其与胃癌病理特征的关系.方法 制备组织芯片,采用免疫组织化学法和原位杂交技术分别检测CD147、MMP-2在170例胃癌组织和30例正常胃黏膜组织中的表达情况.结果 CD147、MMP-2蛋白在胃癌组织的阳性表达率为72.9%和77.1%;CD147、MMP-2 mRNA在胃癌组织中阳性表达率为68.8%和74.7%,均明显高于在正常胃黏膜组织(P<0.05).CD147、MMP-2蛋白和CD147、MMP-2 mRNA与胃癌分化程度无关,但与肿瘤浸润程度、淋巴结转移、临床分期有关(P<0.05).胃癌组织中CD147、MMP-2蛋白和CD147、MMP-2 mRNA的阳性表达,分别具有显著正相关性(P<0.05).结论 检测胃癌组织中CD147、MMP-2的表达,可预估胃癌的浸润和转移,对抗肿瘤综合治疗和预后评估具有重要意义.

MMP-2及CD147在侵袭性垂体腺瘤中的表达及其相互关系的研究

目的检测基质金属蛋白酶(MMP-2)及CD147在侵袭性和非侵袭性垂体腺瘤中的表达,以探讨其与肿瘤侵袭发生的关系及两者之间的相关性。方法用免疫组化SP法和RTPCR方法对55例垂体腺瘤患者标本MMP2及CD147的表达进行检测。结果免疫组化显示,侵袭性垂体腺瘤的MMP-2强阳性及阳性表达率明显高于非侵袭性垂体腺瘤(65.6%和93.8%,13.0%和43.5%,P<0.05),CD147强阳性及阳性表达率明显高于非侵袭性垂体腺瘤(53.1%和96.9%,21.7%和52.2%,P<0.01)。侵袭性垂体腺瘤组MMP-2及CD147mRNA的表达(1.126±0.081,0.887±0.043,P<0.01),明显高于非侵袭性垂体腺瘤组(0.425±0.083,0.179±0.051,P<0.01)。侵袭性腺瘤组中MMP2与CD147的表达成正相关(r=0.73,P<0.05),非侵袭性腺瘤组中MMP-2与CD147的表达无明显相关性(r=0.34,P>0.05)。结论MMP2及CD147的高表达与垂体腺瘤的侵袭性密切相关。MMP-2和CD147可以作为垂体腺瘤侵袭性的2项有效指标。在肿瘤侵袭过程中CD147与MMP-2的产生关系密切。